Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Myeloproliferative neoplasms
Ruxolitinib + Abemaciclib (CDK4/6) Shows 44% SVR35 in Rux-Inadequate-Response Myelofibrosis
Ruxolitinib (a JAK1/2 inhibitor) was combined with abemaciclib (an oral CDK4/6 inhibitor that blocks G1/S cell-cycle progression) in a Phase I 3+3 dose-escalation study in previously treated myelofibrosis with…
NCT05714072 - Trial result
Pancreatic cancer
Cadonilimab (AK104) PD-1/CTLA-4 bispecific + gem/nab-paclitaxel posts 33.9% ORR and 13.8-mo mOS in 1L advanced PDAC
Cadonilimab is a PD-1/CTLA-4 bispecific antibody (AK104) evaluated with gemcitabine + nab-paclitaxel (AG) in the Phase 2, multicenter, open-label COMPASSION-26 study (NCT05859750) as first-line therapy for…
NCT05859750 - Trial result Spotlight
Small cell lung cancer
ZL-1310 (DLL3-targeted topo I ADC) drives 58% intracranial responses in ES-SCLC brain mets
ZL-1310 is a DLL3-targeted antibody–drug conjugate using the TMALIN® platform (protease-cleavable linker delivering a topoisomerase I inhibitor payload) evaluated in a multi-country Phase 1 dose-escalation trial in…
NCT06179069 - Trial result
Colorectal cancer
NG-350A (CD40 agonist oncolytic adenoviral vector) + long-course CRT drives 80% near-cCR at W12 in pMMR LARC (FORTRESS Phase 1b)
NG-350A is an intravenously delivered, tumor-selective oncolytic adenoviral vector engineered to locally express an agonistic anti-CD40 antibody (immune-activating transgene), evaluated with standard long-course…
NCT06459869 - Trial result
Bladder and urothelial cancer
BT5528 (EphA2-targeted Bicycle Drug Conjugate delivering MMAE) + nivolumab shows 30% ORR in EphA2+ post–checkpoint mUC
BT5528 is a low–molecular weight EphA2-targeting Bicycle Drug Conjugate (BDC) linked to the microtubule toxin MMAE via a cleavable linker; here it was combined with nivolumab (anti–PD-1) in a Phase 1/2…
NCT04180371 - Trial result Spotlight
Colorectal cancer
ADG126 (masked anti-CTLA-4) + pembrolizumab + fruquintinib drives 25–50% PRs in 4L MSS CRC (early Ph1b)
ADG126 (muzastotug) is a protease-activated “masked” anti-CTLA-4 IgG1 designed for tumor-selective CTLA-4 engagement, here combined with pembrolizumab (PD-1) and fruquintinib (VEGFR1/2/3 TKI) in a Phase 1b 4th-line…
NCT05405595 - Trial result
Colorectal cancer
FOLFIRI–cetuximab (EGFR mAb) sequencing fails to beat bevacizumab strategy on disease control in RAS/BRAFV600E WT mCRC
STRATEGIC-1 (GERCOR-PRODIGE-39; Phase III, randomized, open-label; NCT01910610) enrolled untreated, unresectable RAS/BRAFV600E wild-type metastatic colorectal cancer (n=263) to compare Arm A (FOLFIRI+cetuximab →…
NCT01910610 - Trial result
Colorectal cancer
BXQ-350 (saposin C nanovesicle; sphingolipid “homeostasis” modulator) + mFOLFOX7/bevacizumab shows 61% ORR with low severe CIPN in 1L mCRC
BXQ-350 is a saposin C–containing nanovesicle designed to allosterically shift dysregulated sphingolipid metabolism (↓GM3/GluCer/S1P; ↑ceramides) and was combined with first-line mFOLFOX7 + bevacizumab in a Phase…
NCT05322590 - Trial result
Colorectal cancer
BI 905711 (TRAILR2/CDH17 bispecific) shows biomarker apoptosis but only stable disease in refractory GI cancers
BI 905711 is a TRAILR2/CDH17 bispecific antibody designed to trigger extrinsic apoptosis signaling in CDH17+ GI tumors; in Phase I monotherapy dose escalation/expansion (NCT04137289) in advanced refractory GI cancers…
NCT04137289 - Trial result
Colorectal cancer
Botensilimab (Fc-enhanced anti-CTLA-4) + balstilimab (anti–PD-1) posts 71% iRECIST DCR in chemo-free 1L “liver-sparing” MSS mCRC
BOT is a 2nd-gen Fc-modified anti-CTLA-4 designed to enhance Treg depletion and myeloid activation, and BAL is an anti–PD-1 antibody; they were tested in a Phase I/II first-line study in anatomically selected Stage…
NCT06268015 - Trial result
Brain and CNS tumors
Marrow-ablative high-dose chemo (AuHCR) plus re-irradiation links to higher 3-year OS in relapsed CNS NGGCT
A multinational retrospective series of relapsed/refractory central nervous system nongerminomatous germ cell tumors (NGGCT) evaluated marrow-ablative high-dose chemotherapy with autologous hematopoietic stem cell…
- Trial result
Neuroendocrine and adrenal tumors
ZL-1310 (DLL3-targeted topo-I ADC) drives 48% ORR in platinum-refractory extrapulmonary NEC (early Phase 1b)
ZL-1310 is a DLL3-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload via a protease-cleavable linker (TMALIN® platform). In the Phase 1b/2 ZL-1310-002 study (NCT06885281), patients with…
NCT06885281 - Trial result Spotlight
Multiple solid tumors
Zedoresertib (WEE1) + Lunresertib (PKMYT1) Shows Early Tumor Shrinkage in CCNE1/FBXW7-Altered Solid Tumors (notably ovarian)
Zedoresertib is an oral, selective WEE1 inhibitor and lunresertib is an oral, selective PKMYT1 inhibitor; dual checkpoint abrogation is designed to force premature mitotic entry under replication stress, driving…
NCT04855656 - Trial result Spotlight
Multiple solid tumors
Elisrasib (D3S-001) GDP-bound KRAS G12C inhibitor drives 62% ORR in mCRC with cetuximab—and 68% ORR as monotherapy in PDAC
Elisrasib (D3S-001) is an oral, next-generation KRAS G12C inhibitor engineered to bind the GDP-bound state and resist growth factor–driven nucleotide exchange; in KRAS G12C–mutant mCRC it was also combined with…
NCT05410145 - Trial result
Multiple solid tumors
BGB-24714 (SMAC mimetic/IAP antagonist) shows no MTD; adds cCRT response signal but chemo-combo activity mixed
BGB-24714 is a selective SMAC mimetic that antagonizes inhibitor-of-apoptosis proteins (IAPs), aiming to restore apoptosis and potentially sensitize tumors to chemotherapy or concurrent chemoradiotherapy (cCRT). In…
NCT05381909 - Trial result
Multiple solid tumors
AU409 transcription regulator (TATA-box modulation) shows 11% PR and multi-month disease control in pretreated HCC
AU409 is a first-in-class oral small molecule designed to modulate transcription at TATA-box regulatory elements, evaluated as monotherapy across two ongoing Phase 1 dose-escalation studies in advanced solid tumors…
NCT05791448 - Trial result
Multiple solid tumors
SynKIR-110 (mesothelin KIR-CAR/DAP12) shows early tumor shrinkage with low-grade CRS in refractory solid tumors
SynKIR-110 is an autologous mesothelin (MSLN)-targeted KIR-CAR T-cell therapy engineered to signal via the KIR/DAP12 multichain immune-receptor module (vs conventional CD3ζ CAR designs), aiming to reduce exhaustion…
NCT05568680 - Trial result
Multiple solid tumors
Tolododekin alfa (ANK-101) anchored IL-12 drives CD8+ influx—but M-MDSC expansion tracks with progression
Tolododekin alfa (ANK-101) is a first-in-class, aluminum hydroxide–anchored IL-12 cytokine designed for prolonged intratumoral retention after intratumoral injection. In the Phase 1 NCT06171750 correlative cohort…
NCT06171750 - Trial result
Multiple solid tumors
PLN-101095 (dual αvβ8/αvβ1 integrin; TGF-β activation blocker) + pembrolizumab delivers 40% iRECIST responses in ICI-secondary–refractory solid tumors
PLN-101095 is a first-in-class oral small-molecule dual αvβ8/αvβ1 integrin inhibitor intended to block latent TGF-β activation in the tumor microenvironment and potentially re-sensitize tumors to PD-1 blockade; it…
NCT06270706 - Trial result
Multiple solid tumors
SGR-3515 Wee1/Myt1 dual inhibitor shows manageable G3/4 AEs and 78% stable disease at 100–135mg in heavily pretreated solid tumors
SGR-3515 is an oral small-molecule dual inhibitor of the cell-cycle checkpoint kinases Wee1 and Myt1, designed to force CDK1 activation and disrupt G2/M control (synthetic-lethal rationale), and is being tested in…
NCT06463340 - Trial result
Multiple solid tumors
M3T01 (anti-FasL) Shows 60% Stable Disease and Clean Early Safety in Refractory Solid Tumors
M3T01 is a fully human IgG4/kappa monoclonal antibody that blocks Fas ligand (FasL), aiming to prevent FasL-mediated apoptosis of tumor-reactive T cells and potentially improve intratumoral T-cell infiltration. In an…
NCT06719362 - New trial
Lymphoma
Phase 2 VG712 anti-CD3 immunotoxin (diphtheria toxin fusion) vs mogamulizumab in MF
Virogen Biotechnology’s CurbMF-001 is a Phase 2, multi-center study in relapsed/refractory mycosis fungoides (stage IB–IVB) after ≥2 prior systemic therapies, with a lead-in dose-finding component (BOIN design; up to…
NCT07529405 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 3 INCB161734 KRAS G12D–selective inhibitor plus chemo in metastatic PDAC
In this randomized, double-blind Phase 3 DAWN-303 trial from Incyte, patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) whose tumors harbor a KRAS G12D mutation are assigned to…
NCT07522073 Registrational - New trial
Head and neck cancer
Phase 2 zanzalintinib (c-MET/VEGFR tyrosine kinase inhibitor) in recurrent/metastatic olfactory neuroblastoma.
This single-arm Phase 2 study at MD Anderson Cancer Center evaluates whether zanzalintinib can control recurrent or metastatic olfactory neuroblastoma (ONB) that is unresectable and not amenable to curative-intent…
NCT07527169 Exploratory - New trial
Melanoma
Phase 2 fianlimab + cemiplimab tests dual LAG-3/PD-1 checkpoint blockade in resectable melanoma.
This Phase 2, open-label, randomized, parallel-assignment trial at UC Irvine evaluates perioperative “total neoadjuvant therapy” using fianlimab plus cemiplimab in patients with surgically resectable melanoma.…
NCT07527325 Exploratory - New trial
Lymphoma
Phase 1b REBEL tests EBRT then epcoritamab/glofitamab CD20×CD3 T‑cell engagers in R/R DLBCL.
This Phase 1b, single-group, open-label study at University of Utah evaluates whether a short course of external beam radiation therapy (up to ~20 Gy, delivered over 5 days) can be safely followed immediately by a…
NCT07528352 Exploratory - New trial
Liver and bile duct cancer
Phase 2 Yttrium-90 TARE beta-radiation embolization versus SBRT photon radiation for HCC
Henry Ford Health System is running REVERT, a single-site, prospective, randomized, open-label Phase 2 trial comparing two definitive local radiation strategies for hepatocellular carcinoma (HCC): transarterial…
NCT07530172 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 1/2 ivonescimab PD-1×VEGF-A bispecific with Dato-DXd TROP2 ADC or osimertinib EGFR TKI
MSK is running a non-randomized, open-label Phase 1/2 trial in metastatic EGFR-activating–mutant NSCLC after prior EGFR TKI therapy, testing a fixed dose of ivonescimab (a PD-1 and VEGF-A–targeted bispecific…
NCT07535437 Exploratory - New trial
Non-small cell lung cancer
Phase 1/2 ivonescimab PD-1×VEGF-A bispecific antibody with platinum chemo + SRS in NSCLC brain mets.
This Memorial Sloan Kettering–sponsored Phase 1/2 study tests ivonescimab (AK112/SMT112)—a tetravalent bispecific antibody that blocks PD-1 on T cells and neutralizes VEGF-A to combine immune checkpoint inhibition…
NCT07535463 Exploratory - New trial
Breast cancer
Pilot feasibility study uses IONM for nerve identification during ALND (ICBN/MBCN monitoring)
University of Cincinnati is running an interventional, pilot feasibility study in breast cancer patients undergoing axillary lymph node dissection (ALND) to see whether intraoperative neuromonitoring (IONM)—a…
NCT07528638 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.